Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  Pyridine compound >  Ethylpyridine >  N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

Basic information Safety Supplier Related

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Basic information

Product Name:
N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine
Synonyms:
  • N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine
  • CS-389
  • JNJ 26854165; JNJ26854165; JNJ-26854165
  • JNJ 26854165
  • SerdeMetan
  • JNJ-26854165 (SerdeMetan)
  • JNJ 26854165 N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine
  • N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine JNJ 26854165
CAS:
881202-45-5
MF:
C21H20N4
MW:
328.41
EINECS:
200-256-5
Product Categories:
  • Inhibitors
  • Inhibitor
Mol File:
881202-45-5.mol
More
Less

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Chemical Properties

storage temp. 
Store at -20°C
solubility 
insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL in DMSO
form 
solid
More
Less

Safety Information

HS Code 
29339900
More
Less

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Usage And Synthesis

Uses

JNJ 26854165 is a p53 activator and HDM2 ubiquitin ligase (MDM2) inhibitor.

Biological Activity

jnj-26854165, also named as serdemetan, is originally developed as an activator of p53, is now regarded as a novel oral human double minute-2 (hdm-2) ubiquitin ligase antagonist. it can increase the level of hdm-2 client proteins, such as p53, by inhibiting the association of hdm-2-client protein complex with the proteosome. it is demonstrated potent anti-proliferative and apoptosis-inducing activity of jnj-26854165 in a broad range of p53 wild type and mutant tumor models. in vivo, jnj-26854165 may induce important differences in efs distribution when comparing to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable all xenografts.j. tabernero, l. dirix, p. schoffski, a. cervantes, j. capdevila, j. baselga, l. van beijsterveldt, h. winkler, s. kraljevic and s. h. zhuang. phase i pharmacokinetic (pk) and pharmacodynamic (pd) study of hdm-2 antagonist jnj-26854165 in patients with advanced refractory solid tumors. journal of clinical oncology (meeting abstracts) may 2009 vol. 27 no. 15s 3514malcolm a. smith, richard gorlick, e. anders kolb, richard lock, hernan carol, john m. maris, stephen t. keir, christopher l. morton, c. patrick reynolds, min h. kang, janine arts, tarig bashir, michel janicot, raushan t. kurmasheva, peter j. houghton. initial testing of jnj-26854165 (serdemetan) by the pediatric preclinical testing program. pediatric blood & cancer. volume 59, issue 2, pages 329–332, august 2012.

target

HDM2

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamineSupplier

Shanghai JiYi Biotechnology Co. Ltd. Gold
Tel
13621943973
Email
sales@shjiyipharmatech.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
021-20908456
Email
sales@BioChemBest.com
VDM Biochemicals
Tel
0330-2528181
Email
sales@vdmbio.com
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)